Onfi (Clobazam) Patent Expiration, LOE Window & CMS Spending
Onfi (Clobazam) by Lundbeck: Off-Patent Genericized (AB Competition), 17 AB generics, $104.4M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Lundbeck |
| FDA Application & Pathway | N202067 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 17 |
| 2024 CMS Total Public Spend | $104.4M |
| 2024 Medicare Part D Spend | $31.4M |
| 2024 Medicaid Spend | $73.0M |
| Reported Wholesale Price Change (CA SB 17) | 8 WAC filings (max 24.8% 2-yr change) |